Low- versus high-dose recombinant Urokinase for the treatment of chronic saphenous vein graft occlusion

American Journal of Cardiology

Volumn 83, Issue 12, 1999, Pages 1623-1628

  Teirstein, Paul S ^a   Lift Mann III, J ^b   Cundey Jr , Paul E ^b   Schechter, Eliot ^b   Carlisle Jacobs, W ^b   Grines, Cindy L ^b   Stagaman, David J ^b   Lansky, Alexandra J ^b   Hultquist, Mitchell A ^b   Kusnick, Barry A ^b   Heuser, Richard R ^b   Kleinert, Hollis D ^b   Popma, Jeffrey ^b  

^a SCRIPPS CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE;

ADULT; ALLERGIC REACTION; ANGIOGRAPHY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAPHENOUS VEIN GRAFT; VEIN OCCLUSION;

ADULT; AGED; ANTICOAGULANTS; CEREBRAL HEMORRHAGE; CHRONIC DISEASE; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT OCCLUSION, VASCULAR; HEPARIN; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATORS; RECOMBINANT PROTEINS; SAPHENOUS VEIN; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033564264     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00163-0     Document Type: Article

References (16)

1. Ambrose JA, Almeida OD, Sharma SK, Torre SR, Marmur JD, Israel DH, Ratner DE, Weiss MB, Hjemdahl-Monsen CE, Myler RK, et al, for the TAUSA Investigators. Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA trial. Circulation 1994;90:69-77.
2. Mehran R, Ambrose JA, Bongu RM, Almedia OD, Israel DH, Torre S, Sharma SK, Ratner DE, for the TAUSA Study Group. Angioplasty of complex lesions in ischemic rest angina: Results of the thrombolysis and angioplasty in unstable angina (TAUSA) trial. J Am Coll Cardiol 1995;26:961-966.
3. Hartmann JR, McKeever LS, Stamato NJ, Bufalino VJ, Marek JC, Brown AS, Goodwin MJ, Cahill JM, Enger EL. Recanalization of chronically occluded saphenous vein bypass grafts by extended infusion of urokinase: initial results and short-term clinical follow-up. J Am Coll Cardiol 1991;18:1517-1523.
4. Hartmann JR, McKeever LS, O'Neill WW, White CJ, Whitlow PL, Gilmore PS, Doorey AJ, Galichia JP, Engler EL. Recanalization of chronically occluded aortocoronary saphenous vein bypass grafts with long-term, low dose direct infusion of urokinase (ROBUST): a serial trial. J Am Coll Cardiol 1996;27:60-66.
5. Sheehan F, Braunwald E, Canner P, Dodge HT, Gore J, Van Natta P, Passamani ER, Williams DO, Zaret B, and Co-Investigators. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis In Myocardial Infarction (TIMI) phase I trial. Circulation 1987;72:817-829.
6. Gronenschild E, Janssen J, Tijdens F. CASS II: A second-generation system for off-line and on-line quantitative coronary angiography. Cathet Cardiovasc Diagn 1994;33:61-75.
7. Escaned J, Baptista J, Di Mario C, Haase J, Ozaki Y, Linker DT, de Feyter PD, Roelandt JRTC, Serruys PW. Significance of automated stenosis detection during quantitative angiography: insights gained from intracoronary ultrasound. Circulation 1996;94:966-972.
8. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94:1528-1536.
9. Harrington RA, Lincoff AM, Califf RM, Holmes DR Jr., Berdan LG, O'Hanesian MA, Keeler GP, Garratt KN, Ohman EM, Mark DB, Jacobs AK, Topol EJ, for the CAVEAT Investigators. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the coronary angioplasty versus excisional atherectomy trial (CAVEAT). J Am Coll Cardiol 1995;25:1693-1699.
10. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implications of creatine kinase elevation following elective coronary artery interventions. JAMA 1997;277:461-466.
11. Tardiff BE, Califf RM, Tcheng JE, Lincoff AM, Sigmon KN, Harrington RA, Mahaffey KW, Teirstein P, Heinsimer J, Topol EJ, for the IMPACT-II Investigators. Post-intervention cardiac enzyme elevations: prognostic significance in IMPACT II (abstr). J Am Coll Cardiol 1996;27(suppl A):83A.
12. Redwood SR, Popma JJ, Kent KM, Pichard AD, Satler LF, Mintz GS, Hong MK, Bucher TA, Merritt AT, Leon MB. Predictors of late mortality zollowing ablative new-device angioplasty in native coronary arteries (abstr). J Am Coll Cardiol 1996;27(suppl A):167A.
13. Kahn JK, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Shimshak TM, Ligon RW, Hartzler GO. Initial and long-term outcome of 83 patients after balloon angioplasty of totally occluded bypass grafts. J Am Coll Cardiol 1994;23:1038-1042.
14. Safian RD, Grines CL, May MA, Lichtenberg A, Juran N, Schreiber TL, Pavlides G, Meany TB, Savas V, O'Neill WW. Clinical and angiographic results of transluminal extraction coronary atherectomy in saphenous vein bypass grafts. Circulation 1994;89:302-312.
15. Popma JJ, Leon MB, Mintz GS, Kent KM, Satler LF, Garrand TJ, Pichard AD. Results of coronary angioplasty using the transluminal extraction catheter. Am J Cardiol 1992;70:1526-1532.
16. Fajadet J, Doucet S, Caillard J. The Hydrocatheter, a new concept of treatment of diseased saphenous vein graft: in vitro experimentation (abstr). Circulation 1992;86:1-456.